Showing 1 - 7 of 7 Hematologic Cancers

Status: Open Not Enrolling

Investigator: Shilpan Shah

Study Coordinator: Danielle Grbavac

Phone: 346.238.4456

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of th ... Read more >

Status: Enrolling

Investigator: Siddhartha Ganguly

Study Coordinator: Danielle Sewall

Phone: 346.238.2674

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab i ... Read more >

Status: Open Not Enrolling

Investigator: Shilpan Shah

Study Coordinator: Danielle Grbavac

Phone: 346.238.4456

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants may or may not have already had treatment for their cancer. Participation could last up to six y ... Read more >

Status: Enrolling

Investigator: Shilpan Shah

Study Coordinator: Danielle Sewall

Phone: 346.238.2674

This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort) ... Read more >

Status: Open Not Enrolling

Investigator: Siddhartha Ganguly

Study Coordinator: Danielle Grbavac

Phone: 346.238.4456

A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma. ... Read more >

Status: Open Not Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Mohamed Elhadi

Phone: 214.709.5752

This is a laboratory-based study supported by NIH funding. It is aimed to explore the therapeutic effects of novel molecules or antigens to treat hematologic diseases. In order to complete these studies, samples including peripheral blood, bone ... Read more >

Status: Enrolling

Investigator: Shilpan Shah

Study Coordinator: Danielle Grbavac

Phone: 346.238.4456

This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with ... Read more >